Previous Article | Next Article ![]()
Journal of Clinical Microbiology, July 2004, p. 3232-3239, Vol. 42, No. 7
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.7.3232-3239.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Gary J. Vora,1,2,
Dzung Thach,1,2 Elizabeth Walter,2,3 David Metzgar,2,4 Clark Tibbetts,2 and David A. Stenger1,2*
Center for Bio/Molecular Science & Engineering, Naval Research Laboratory, Washington, DC 20375,1 Epidemic Outbreak Surveillance Consortium, USAF/SGXFalls Church, Virginia,2 Lackland Air Force Base, San Antonio, Texas 78236,3 Respiratory Disease Laboratory, Naval Health Research Center, San Diego, California 921864
Received 3 September 2003/ Returned for modification 9 February 2004/ Accepted 2 April 2004
|
|
|---|
|
|
|---|
The human adenoviruses are a family of viruses consisting of 51 serotypes (5, 32). Distinction of adenovirus serotypes is based on the neutralization of infectivity, which is type specific and which is directed against epitopes on the hexon protein, and hemagglutination inhibition, which is directed against epitopes on the fiber protein (27, 35). The 51 serotypes can be further divided into six subgroups (subgroups A to F) according to their nucleic acid homologies, fiber protein characteristics, and biological properties (32). In the United States, adenovirus serotype 4 (Ad4) and Ad7 are most often associated with adult respiratory tract infections, followed by Ad21 and Ad3 (37); and the ARDs caused by these adenoviruses are difficult to distinguish clinically from other viral or bacterial respiratory infections (16). Thus, the use of clinical microbiological methods is necessary for absolute detection of adenovirus infection.
Conventional methods for adenovirus detection and serotyping involve testing by viral shell culture, observation for cytopathic effects, and microneutralization assays (24) or serotyping with virus serotype-specific antisera (11). These methods produce confirmatory results in 3 days to 3 weeks, depending on the specimen source and the concentration of viable virus within the specimen (6). Identification in this manner is heavily dependent upon the interpretation of results by experienced personnel, is time-consuming and labor-intensive, and often produces equivocal results. In addition, the acquisition of assay results generally takes too long to have any relevance for the treatment or quarantine of infected individuals.
Recently, effective alternatives for the rapid identification of adenoviruses have been developed through the use of modern molecular techniques such as the PCR (2), multiplex PCR (26, 29, 36, 37), PCR plus sequencing (33), and restriction endonuclease analysis (1, 7, 10, 21, 31). Although PCR-based methods have clearly facilitated the detection of adenoviruses, conventional gel-based amplicon detection techniques require multistep procedures and special laboratory setup and are entirely reliant upon DNA fragment size estimation and analysis for positive identification. More recently, fluorogenic real-time PCR has been developed as a type-specific diagnostic system (17, 28) which provides a sensitive and rapid assay for adenovirus identification. However, the use of PCR as a generic detection system for the differentiation of the 51 different adenovirus serotypes is still labor-intensive and subject to equivocal results.
With the substantial progress in microarray technology, it is now possible to combine the sensitivity afforded by nucleic acid amplification with the specificity afforded by DNA-DNA hybridization for the detection of viruses pathogenic for humans (4, 19, 20, 23, 34). By taking advantage of this progress, we sought to develop a two-checkpoint assay that would facilitate the rapid detection of adenoviruses by combining real-time fluorogenic multiplex PCR with microarray analysis capable of detecting and differentiating the most common adenoviruses associated with human respiratory tract infections: serotypes 3, 4, 7, 16, and 21. Three target genes, E1A, hexon, and fiber, were chosen for use in diagnostic probe design on the basis of their functions and locations within the linear adenoviral genome. E1A is located at the 5' end of the adenovirus genome and encodes a trans-acting transcriptional regulatory factor that is necessary for transcriptional activation of early genes (32). The hexon and fiber genes, which are located in the middle and the 3' end of the adenovirus genome, encode antigenic determinants
and
, respectively, which determine the viral serotype (9). Thus, in this study we describe a novel and rapid approach for the detection and serotyping of ARD-causing adenoviruses by targeting the nucleic acid determinants that give rise to serotype by microarray hybridization. Using the two-checkpoint scheme, our results demonstrate the ability of the assay to detect adenoviruses from laboratory and clinical samples in less than 60 min and to determine the serotype in less than 90 min. Using an alternate amplification and hybridization strategy, we also demonstrate a detection sensitivity of 1 to 100 genome copies for laboratory and clinical samples, concordance of the assay results with those of conventional adenovirus identification methods, and the ability to detect adenoviral contamination events in a single assay.
|
|
|---|
Primer design and PCR amplification. The primers used for PCR are based on an alignment of the following E1A, fiber, and hexon gene sequences available from GenBank (GenBank accession numbers are given in parentheses): for the E1A gene, Ad11 (NC_004001), Ad2 (NC_001405), Ad3 (AF492352), Ad4 (M14918), and Ad7 (X03000); for the fiber gene, Ad2 (AJ278921), Ad5 (M18369), Ad3 (X01998), Ad4 (X76547), Ad7 (M23696), Ad16 (U06106), and Ad21 (U06107); and for the hexon gene, Ad3 (X76549), Ad4 (X84646), Ad6 (AF161560, X67710, and Y17245), Ad7 (AF053087 and X76551), Ad16 (X74662), and Ad21 (AB053166). The E1A gene alignment was assembled by using the Ad3, Ad4, Ad7, Ad21, Ad11, and Ad2 E1A gene sequences, whereas the hexon gene alignment was assembled by using the Ad3, Ad4, Ad6, Ad7, Ad16, and Ad21 sequences and the fiber gene alignment was assembled by using the Ad2, Ad3, Ad4, Ad5, Ad7, Ad16, and Ad21 sequences. The sequences of the four primer sets are listed in Table 1. PCRs were performed in 50-µl volumes containing 20 mM Tris-HCl (pH 8.4); 50 mM KCl; 2 mM MgCl2; 200 µM each dATP, dTTP, and dGTP' 20 µM each dCTP and biotin-14-dCTP (Invitrogen Life Technologies, Carlsbad, Calif.); 200 to 500 nM primers; 2 U of Platinum Taq DNA polymerase (Invitrogen Life Technologies); and 106 copies (1 to 4 µl of a clinical specimen or DNA extract) of adenoviral genomic DNA. The amplification reaction was carried out in Peltier PTC225 thermal cycler (MJ Research Inc., Reno, Nev.) with preliminary denaturation at 94°C for 3 min, followed by 40 cycles of 94°C for 30 s, 50°C for 30 s, and 72°C for 40 s, with a final extension at 72°C for 10 min. The amplified products were electrophoresed on 1.5 to 3% TAE (Tris-acetate-EDTA) agarose gels and visualized by ethidium bromide staining. When the R.A.P.I.D. LightCycler instrument (Idaho Technology Inc., Salt Lake City, Utah) was used for real-time PCR, 20-µl reaction volumes were prepared containing 0.2 µl FastStart Reaction Mix SYBR Green I (Roche Applied Science, Indianapolis, Ind.); 20 mM Tris-HCl (pH 8.4); 50 mM KCl; 2 mM MgCl2; 200 µM each dATP, dTTP, and dGTP; 20 µM each dCTP and cyanine 5 (Cy5)-dCTP (Amersham Biosciences Corp., Piscataway, N.J.); 200 to 500 nM primers; 2 U of Platinum Taq DNA polymerase (Invitrogen Life Technologies); and 106 copies of adenoviral genomic DNA. The amplification reaction was performed with a preliminary denaturation step at 94°C for 3 min, followed by 40 three-step cycles of 95°C for 0 s, 45°C for 10 s, and 72°C for 30 s.
|
View this table: [in a new window] |
TABLE 1. Sequences of generic primers used for multiplex PCR amplification
|
Probe design and microarray fabrication. The PCR amplification products of the E1A, hexon, and fiber genes of adenovirus strains of serotypes 3, 4, 6, 7, 16, and 21 were resequenced and aligned by using the ClustalW (version 1.8) program. On the basis of the alignment, two long unique oligonucleotide probes (between 60 and 72 nucleotides) specific for each of the three genes of each serotype were selected for representation on the microarray. Due to the highly conserved nature of the subgroup B1 E1A gene, a single probe specific for the E1A genes of serotypes 3, 16, and 21 was printed in duplicate. Searches were conducted with the BLAST algorithm to exclude probes with high degrees of similarity to nonadenovirus sequences and to predetermine the levels of cross-reactivity between selected probes on the basis of adenovirus evolutionary relatedness and sequence conservation. Probe quality was confirmed with the Array Designer (version 2.02) program (Premier Biosoft, Palo Alto, Calif.), and minor adjustments were made to obtain a melting temperature range of 70 to 81°C. A final set of 33 unique oligonucleotide probes was selected to detect and differentiate serotypes 3, 4, 6, 7, 16, and 21. The probe sequences and designations can be found at http://nrlbio.nrl.navy.mil/Research/Stenger/Stenger.asp. Once the probes were designed, they were synthesized with a 5' amino modifier and a 12-carbon spacer (Qiagen Operon, Alameda, Calif.) and spotted onto glass slides modified with 3-aminopropyltriethoxysilane (for silanization) plus 1,4-phenylene diisothiocyanate (as a cross-linker) for covalent probe immobilization, as described previously (3). Oligonucleotides were printed in 100 mM carbonate-bicarbonate buffer (pH 9.0) at a concentration of 50 pmol/µl with a Virtek ChipWriter Pro contact printer at KamTek Inc. (Gaithersburg, Md.). The printed slides were stored desiccated at room temperature.
Microarray hybridization and processing. Prior to hybridization, the slides on which the oligonucleotides were printed were blocked with a 1.5% bovine serum albumin-1.5%casein solution (pH 7.4) for 15 min at room temperature and outfitted with Secure-Seal SA50 Hybridization Chambers (Schleicher & Schuell, Keene, N.H.). Cy5-labeled samples that were amplified with the R.A.P.I.D. LightCycler instrument (for the two-checkpoint detection scheme) were brought to a final volume of 50 µl with 4x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and 0.2% sodium dodecyl sulfate (SDS) (final concentrations). The samples were then denatured for 3 min at 98°C and immediately applied to microarrays placed on a 58°C heating block. After a 5-min hybridization, the slides were washed twice with 4x SSC-0.2% SDS buffer for 3 min at 60°C, once with 1x SSC buffer for 1 min at room temperature, and once with distilled H2O for 5 s and were then dried under a nitrogen stream. They were then ready to be scanned.
Hybridization buffer was also added to the biotinylated samples that were amplified with the Peltier PTC225 thermal cycler to achieve a total volume of 75 µl with 4x SSC-0.2% SDS (final concentrations). The biotinylated target hybridization sample was also denatured for 3 min at 98°C and then immediately applied to the microarray. Biotinylated amplicon hybridizations were performed for 1 h at 58°C in a GeneChip 640 hybridization oven (Affymetrix, Santa Clara, Calif.) rotating at 35 rpm. After hybridization, the slides were washed twice with 4x SSC-0.2% SDS buffer for 5 min at 60°C and once with 1x SSC buffer for 2 min at room temperature. Hybridization events were detected by the sequential addition of Cy5-conjugated monoclonal mouse anti-biotin immunoglobulin G (IgG; Jackson ImmunoResearch, West Grove, Pa.) and Cy5-conjugated goat anti-mouse IgG (Jackson ImmunoResearch), in which each antibody was incubated for 15 min at room temperature. The slides were then subjected to three rinses with 1x SSC for 3 min each time at room temperature and a final rinse with distilled H2O. Once the slides used for both hybridization methods were dried under a nitrogen stream, the slides were subsequently scanned with a ScanArray Lite confocal laser scanning system (Perkin-Elmer, Torrance, Calif.). The microarray images were captured at a laser power of 80 and a photomultiplier tube gain of 80, and the signal from each microarray element was considered positive only when its fluorescence intensity was three times or greater than the neighboring background fluorescence intensity.
Quantification of Ad4 and Ad7 in clinical samples.
For sensitivity assessments, real-time PCR assays were conducted on an iCycler instrument (Bio-Rad Laboratories, Hercules, Calif.) to determine the number of adenovirus genomes in each sample. The findings for the samples were compared to those for fivefold serial dilutions of Ad4 and Ad7 genomic DNA templates of known copy numbers, ranging from 2 x 103 to 1.25 x 106 copies, by using primers AdE1A-F and AdE1A-R. The adenovirus genomic copy number for standard curve generation was calculated by isolating Ad4 and Ad7 viral DNA from the supernatants of infected A-549 cells and using the following conversion factor: 0.384 fg = a single adenoviral genome of
35 kb (31). Briefly, clarified supernatants were sequentially treated with DNase to remove extracellular DNA and proteinase to release adenoviral DNA. The viral DNA was then spin purified (Mo Bio Laboratories, Solana Beach, Calif.), and the DNA concentration was determined by spectroscopy. Real-time PCR mixtures consisted of 1x SYBR Green I PCR Master Mix (Applied Biosystems, Foster City, Calif.) and 200 nM (each) sense and antisense primers. Following a preliminary denaturation step at 94°C for 10 min, the reaction mixtures were subjected to 35 cycles of 94°C for 30 s, 50°C for 30 s, and 72°C for 40 s. For each test target the threshold cycles (CT) were averaged for duplicate reactions and the values were compared to the linear trend line for the plotted standards. The target sample copy number was extrapolated from the CT values for the test samples that fell within the range of the linear trend line for the plotted standards.
Adenovirus culture and immunodetection. A-549 cells were maintained in Dulbecco modified Eagle medium containing 10% fetal bovine serum at 37°C and 5% CO2 in 24-well plates. At the time of infection, the growth medium was replaced with a 1:10,000 dilution of an infectious inoculum of Ad4 (ATCC VR-4) and was maintained at 37°C. The infected cells were fixed at 72 h postinfection for adenovirus immunodetection. All infected samples were processed in parallel and were stained with either Ad3 rabbit antiserum (VR-1080AS/RB), Ad4 rabbit antiserum (VR-1081AS/RB), or Ad7a rabbit antiserum (VR-1084AS/RB) (ATCC) and visualized with a fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG secondary antibody (Jackson ImmunoResearch, West Grove, Pa.). Once the cells were processed, they were viewed and photographed on an ECLIPSE E800 epifluorescence microscope (Nikon, Melville, N.Y.).
|
|
|---|
|
View larger version (18K): [in a new window] |
FIG. 1. Electrophoretic profiles of the amplicons obtained by multiplex PCR with representative Ad prototype strains from each subgroup. A 1-kb DNA ladder is presented in the unmarked lane on the far left, and the amplicon designations are given on the right. The Ad serotypes (below the brackets) and Ad subgroups (above the brackets) are also indicated. Fiber 1, amplicons generated by primers AdB1 and AdB2 (primers specific for B-subgroup fiber genes); Fiber 2, amplicons generated by primers AdfibF3 and AdfibR3 (primers designed to amplify Ad4 and Ad6 fiber genes).
|
![]() View larger version (41K): [in a new window] |
FIG. 2. Combination fluorogenic multiplex PCR and microarray hybridization-based detection scheme for human adenoviruses. (A) Clinical sample collection (throat swab or nasal wash); time elapsed, 0 min. Step 1, generic multiplex PCR amplification reaction setup including Cy5-dCTP and SYBR Green I dye for real-time detection (sample preparation is not necessary for appropriately diluted clinical samples); time elapsed, 10 min. (B and C) Nucleic acid amplification with the R.A.P.I.D. LightCycler instrument. SYBR Green I dye intercalation permits real-time monitoring of the amplification reactions. When real-time monitoring resulted in a positive detection reaction, the amplified material was subsequently hybridized to the microarray for serotype determination; time elapsed, 35 min (laboratory sample) or 58 min (clinical sample). Step 2, 40-cycle R.A.P.I.D. amplification completed; time elapsed, 68 min. (D) Positive reaction sample hybridization and serotype determination. The hybridization results confirmed and provided the serotype determinations for true-positive amplification reactions and/or elucidated false-positive amplicons from the real-time monitoring reactions; time elapsed, 90 min.
|
![]() View larger version (20K): [in a new window] |
FIG. 3. Microarray hybridization patterns of representative serotypes from adenovirus subgroups B1, B2, C, and E. The numbers in the lower left corners of each array indicate the adenovirus serotype. White circles outline weakly positive signals. The white rectangle on the right side of each array outlines a set of unrelated spotted Cy3-labeled probes (+) used for array orientation. All probes specific for a particular serotype are oriented in rows (the serotype designation can be found on the right or left of each array), whereas the unique probe designation (E1 and E2, serotype-specific E1A probes; H1 and H2, serotype-specific hexon probes; and F1 and F2, serotype-specific fiber probes) can be found above each array. All probes targeting the same gene are oriented in columns.
|
|
View this table: [in a new window] |
TABLE 2. Microarray-based detection sensitivity of Ad4 and Ad7 postamplificationa
|
Simultaneous detection of multiple adenovirus serotypes. The scheme with a combination of degenerate primer amplification and microarray-based detection should allow the identification of multiple adenovirus serotypes in a single sample. A surprising demonstration of this capability can be found in Fig. 4. An aliquot from a previously unopened ampoule of Ad4 prototype strain VR-4 from ATCC was amplified and tested by using the adenovirus microarray. The hybridization profile generated clearly suggested the coexistence of Ad3 and Ad4 (Fig. 4A). To determine whether the sample material was contaminated with Ad3 DNA or viable Ad3, we inoculated the sample onto a monolayer of A-549 cells. Immunodetection of Ad4 VR-4-infected A-549 cells revealed the presence of adenoviral nuclear inclusions with Ad4-specific antiserum (Fig. 4B) and Ad3-specific antiserum (Fig. 4C) but not with Ad7a-specific antiserum (Fig. 4D). Thus, the initial microarray-based observation indicating the presence of both Ad3 and Ad4 serotypes in Ad4 VR-4 was confirmed by conventional adenovirus serotyping methods.
![]() View larger version (81K): [in a new window] |
FIG. 4. Microarray-based detection of Ad3 contamination of an ATCC Ad4 stock (VR-4) and cell culture verification. (A) Multiplex PCR and microarray analysis suggested the presence of two adenoviral serotypes (Ad3 and Ad4) in ATCC VR-4. A-549 cells were inoculated with ATCC VR-4 and immunostained at 72 h postinfection with Ad4-specific rabbit antiserum (B), Ad3-specific rabbit antiserum (C), or Ad7a-specific rabbit antiserum (D) and a fluorescein isothiocyanate-conjugated secondary anti-rabbit antibody. The white arrowheads in panels B and C indicate characteristic adenoviral nuclear inclusions (not seen in panel D), confirming the presence of both Ad3 and Ad4 in ATCC VR-4.
|
|
|
|---|
Three critical parameters, target selection, amplification strategy, and probe selection and design, were interrogated for the development of a rapid high-fidelity adenovirus detection platform. (i) The E1A, hexon, and fiber genes were targeted for amplification and diagnostic probe design on the basis of their functions, locations within the linear adenoviral genome, and levels of primary sequence conservation. The E1A gene, located at the 5' end of the adenovirus genome, is highly conserved within and among subgroups. The hexon and fiber genes, which are located in the middle and the 3' end of the adenovirus genome, respectively, encode the antigenic determinants that give rise to serotype. In comparison to other molecular characterization methods that base identification upon a single diagnostic region, we found that the targeting of three dispersed genetic loci for characterization was necessary to reduce misidentification due to hybridization with related primary sequences and genomic plasticity. This is a particularly important feature, as recombination between adenoviruses contributes to the evolution and diversity of viral serotypes (14, 32). (ii) The amplification strategy used degenerate PCR primers that were designed to target conserved regions of the E1A, hexon, and fiber genes that flank variable or hypervariable regions. These primers reliably and consistently amplified the three target regions from adenovirus strains of serotypes 3, 4, 6, 7, 16, and 21 by both amplification protocols (real-time and conventional PCR). (iii) Finally, serotype determination (via the capture of adenovirus serotype-specific DNA) was achieved by hybridizing the amplicons to covalently immobilized long oligonucleotide probes. An important point is that the probes were designed on the basis of the alignments of the six ARD-associated prototype strains. However, the inherent properties of long oligonucleotide probes (18) permit the hybridization of targets that are not perfectly complementary and thus allowed the successful detection and serotyping of primary clinical isolates. In addition to providing a means for hybridization-based identification of clinically relevant ARD-associated adenoviruses, similar molecular characterization approaches may provide assistance in molecular epidemiological surveillance, identifying novel adenoviral recombinants, and determining serotype prevalence in clinical trials of experimental vaccines (4).
PCR amplification is highly sensitive but often suffers from low levels of specificity. By combining the sensitivity of multiplex PCR amplification with the specificity of DNA-DNA hybridization, we have attempted to avert the trade-off between specificity and sensitivity that is often made during evaluations of detection assays. The microarray profiles generated in this study permit the unequivocal identification of the ARD-associated serotypes because of hybridization specificity. This specificity (manifested as the absence of confounding false-positive fluorescent signals) permitted the detection of coexisting adenoviral serotypes in a single assay. In this study we were able to detect the contamination of an ATCC Ad4 prototype strain stock (VR-4) with Ad3. Although unexpected, the initial observation was confirmed by a more traditional method of adenovirus detection: the immunodetection of characteristic adenoviral nuclear inclusions in infected A-549 cells (Fig. 4). On the basis of its specificity, this assay provides the potential to detect coinfections, contamination events, and, possibly, adenoviral recombination events. Assay specificity was further highlighted by the fact that degenerate multiplex PCR amplicons from representative members of subgroups A, D, and F (Fig. 1) could be visualized electrophoretically but did not generate microarray hybridization profiles. Thus, a positive result by real-time PCR (checkpoint 1) but the absence of a microarray hybridization profile (checkpoint 2) may indicate the presence of a serotype from subgroup A, D, or F. On its own, the real-time degenerate multiplex PCR amplification assay provided an opportunity for adenovirus detection (detection of any of the representative prototype strains from subgroups A to F tested), but specific serotype determination for subgroups B1, B2, C, and E could be made only when the multiplex PCR was coupled with microarray hybridization.
It is unknown how many adenoviral organisms are required to cause upper respiratory tract infection in humans. The sensitivity of the microarray-based detection assay was 103 genomic copies when clinical samples were assayed directly. This sensitivity is comparable to that of PCR-restriction fragment length polymorphism analysis (31). As expected, extraction of DNA from the same clinical samples resulted in a 100-fold increase in Ad4 detection sensitivity and a 10-fold increase in Ad7 detection sensitivity. The data are consistent with previous findings that suggest that inhibitory substances in clinical samples interfere with the efficiency of PCR amplification reactions (6). Nevertheless, the ability to detect and serotype clinically relevant strains directly from two of the most common types of adenovirus-infected clinical samples, nasal wash and throat swab specimens in transport medium, establishes the flexibility of the assay. Although sequential PCR and real-time fluorogenic PCR have lower detection limits (8, 17), the capability of the microarray-based detection method obviates the need for the additional equipment and reagents required for sample preparation and provides more information per assay. More importantly, the sensitivity demonstrated was in concordance with those of the cell culture and neutralization assays used at present for the detection of adenoviruses from clinical samples, and serotypes were determined in a matter of hours, not 3 days to 3 weeks.
By use of the two-checkpoint scheme with the R.A.P.I.D. LightCycler instrument, real-time PCR provided an indication of the presence of adenoviruses in less than 1 h; this was followed by microarray hybridization for serotype identification, for a total expired time of PCR and microarray hybridization of 90 min. In addition to the R.A.P.I.D. LightCycler instrument's principal benefit, speed of detection, its use for front-end real-time PCR amplification may also have value for quantitation, as the viral load is a factor that has been suggested to potentially provide a predictive value for disseminated adenovirus disease (15). Whether we used the two-checkpoint scheme with the R.A.P.I.D. LightCycler instrument or the alternate biotinylated sample method, the unique hybridization patterns generated enabled us to detect and differentiate adenovirus serotypes in a matter of 1.5 to 4.0 h, not days or weeks (Fig. 3). For the timely molecular analysis-based detection of adenoviruses from clinical samples, this methodology compares favorably to generic real-time TaqMan PCR assays (
60 min, excluding DNA extraction) (14), generic direct PCR assays (6 h) (7), and nested PCR assays (6 to 24 h) (25), which have recently been described in published reports. Although each documented method could effectively detect adenoviruses in clinical samples, none presented the ability to determine the adenovirus serotype without further experimentation. Moreover, this methodology also compared favorably to broader assays targeting the detection of other human pathogenic viruses by microarray hybridization: orthopoxviruses (6 h) (23), rotaviruses (>4 h) (4), hepatitis B virus (
12 h) (20), and human papillomavirus (>6 h) (19). Thus, from the time of sample collection to the times of pathogen detection and diagnostic identification, the experimental protocol presented provides the most rapid assay identified to date. The ability to detect adenovirus infection and transmission rapidly may provide the opportunity to separate infected individuals in a timely manner to curb outbreaks in military training facilities. In addition, microarray-based epidemiological surveillance can also aid in accurate determination of the serotype of circulating viral strains and the prevalence of adenoviral coinfections, thus providing valuable information that may affect the next generation of vaccine design.
In conclusion, the amplification and microarray-based detection system described here provides a rapid and sensitive platform for the detection of ARD-associated adenoviruses, with the time from sample collection to positive identification of the adenovirus serotype being a matter of hours. At present, in military training environments and other settings where individuals are highly susceptible to outbreaks of acute respiratory illness, this assay could facilitate the identification of adenovirus isolates in support of preventative measures, timely treatment, and epidemiological investigations. The predominance of serotypes Ad4 and Ad7 in the clinical samples tested highlights the reemergence of serotypes against which vaccination previously provided protection in military environments (12). The speed and accuracy of the two-checkpoint detection scheme demonstrate the utility of the scheme not only for the detection of emerging or reemerging infectious diseases (as in the case of adenoviruses) but also, if appropriately applied, for the detection of more immediate biological threat agents.
This work was funded in part by the Office of Naval Research and the Defense Threat Reduction Agency, Michael Collin, EOS-AF/SGR. B. Lin and G. J. Vora are National Research Council postdoctoral fellows.
The opinions and assertions contained herein are those of the authors and are not to be construed as those of the U.S. Navy or the U.S. Department of Defense.
B.L. and G.J.V. contributed equally to these studies. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»